GAMMAPLEX SUMMARY
Gammaplex is a ready to use sterile solution of polyclonal human Immunoglobulin G for IV administration.
Gammaplex is an Immune Globulin Intravenous (Human), 5% Liquid indicated for the replacement therapy of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
|
NEWS HIGHLIGHTSMedia Articles Related to Gammaplex (Human Immunoglobulin G)
Acquired Immunodeficiency Syndrome
Source: MedicineNet Breastfeeding Specialty [2013.05.21]
Title: Acquired Immunodeficiency Syndrome
Category: Diseases and Conditions
Created: 2/3/2010 12:31:00 PM
Last Editorial Review: 5/21/2013 12:00:00 AM
Human Immunodeficiency Virus
Source: MedicineNet Amyotrophic Lateral Sclerosis Specialty [2013.04.03]
Title: Human Immunodeficiency Virus
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/3/2013 12:00:00 AM
New Immune Disease Cripples White Cells (CME/CE)
Source: MedPage Today Oncology/Hematology [2013.06.11]
(MedPage Today) -- A newly-described immunodeficiency syndrome of neutrophil defects, bone marrow fibrosis, nephromegaly, and life-threatening infections arises from a genetic mutation that impairs movement of proteins within cells, researchers found.
How HIV Makes Immune Cells Commit Suicide
Source: HIV / AIDS News From Medical News Today [2013.06.06]
A new study from the US shows how the human immunodeficiency virus (HIV) causes infected immune cells to commit suicide. The researchers believe the finding is an important lead on how to preserve the immune systems of people infected with the virus that causes AIDS...
Researchers Employ Mathematical Models To Better Combat HIV
Source: HIV / AIDS News From Medical News Today [2013.06.04]
The first few hours to days following exposure to human immunodeficiency virus (HIV) can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this stage makes it very difficult to study these events in humans or animal models...
Published Studies Related to Gammaplex (Human Immunoglobulin G)
Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following
vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle
vaccine. [2012]
The exploratory immunogenicity objective of this analysis was to characterize the
titer of vaccine human papillomavirus (HPV)-type immunoglobulins in both
peripartum maternal blood and the cord blood of infants born to women who
received blinded therapy.
Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. [2011.02]
Attenuated live oral typhoid vaccine candidate CVD 909 constitutively expresses Salmonella Typhi capsular polysaccharide antigen (Vi). A randomized, double-blind, heterologous prime-boost clinical study was conducted to determine whether immunity to licensed parenteral Vi vaccine could be enhanced by priming with CVD 909...
Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral
boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S.
Typhi-specific IgA and IgG B memory cells in humans. [2011]
Attenuated live oral typhoid vaccine candidate CVD 909 constitutively expresses
Salmonella Typhi capsular polysaccharide antigen (Vi). A randomized,
double-blind, heterologous prime-boost clinical study was conducted to determine
whether immunity to licensed parenteral Vi vaccine could be enhanced by priming
with CVD 909...
Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. [2010.12]
Merck V710 is a novel vaccine containing the conserved Staphylococcus aureus iron surface determinant B shown to be protective in animal models. A phase I, multicenter, double-blind study of the dose range was conducted to assess the immunogenicity and safety of an adjuvanted liquid formulation of V710...
Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. [2010.11]
BACKGROUND: Serological indicators of human papillomavirus (HPV) infection are being used to differentiate HPV-naive from previously infected women in vaccine and epidemiologic/clinical studies. We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25... CONCLUSIONS: The increasing seroprevalence observed with time since first sex suggests that HPV serology is a cumulative marker of HPV exposure. However, many DNA infected women were seronegative; thus, serology is an imperfect measure of past exposure to cervical HPV, at best. Additionally, we found no evidence of assay cross-reactivity.
Clinical Trials Related to Gammaplex (Human Immunoglobulin G)
A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) [Recruiting]
The primary objective is to determine if BPL's GAMMAPLEX raises the platelet count of
subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical
control. The secondary objectives are: 1) to determine the safety of GAMMAPLEX at the
dosage used in this study. 2) to determine if GAMMAPLEX maintains platelet counts of ³ 50 x
109/L in subjects with chronic ITP for a period of time similar to that of a historical
control.
Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage [Recruiting]
The investigators want to test whether infusions of intravenous immunoglobulin - a blood product known to modify immune responses - in early pregnancy will increase the chance of a
subsequent live birth in women with three or more miscarriages after a birth and a total of
at least four miscarriages. This will be done in a trial where 82 patients will be randomly
allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency [Recruiting]
The purpose of this open-label study is to evaluate the pharmacokinetics, safety, and
tolerability of subcutaneously (SC; under the skin) administered GAMUNEX®-C compared to
intravenously (IV; through the vein) administered GAMUNEX®-C in subjects 2-16 years of age
with Primary Immunodeficiency.
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency [Recruiting]
The main objective is to determine the efficacy of Gammaplex by measuring the number of
serious acute bacterial infections during treatment with Gammaplex over a 12 month period.
The secondary objectives are to assess the safety and tolerability of Gammaplex and to
compare the data collected from adult subjects with PID from the GMX01 study
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy [Not yet recruiting]
The purpose of the study is to see if administering intravenous immune globulin (IVIG)
(putting immune globulin directly into your blood) helps to improve the symptoms of
orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality
of life in men and women who have autoimmune autonomic ganglionopathy (AAG).
Reports of Suspected Gammaplex (Human Immunoglobulin G) Side Effects
International Normalised Ratio Decreased (4),
Pulmonary Embolism (3),
Drug Interaction (2),
Headache (2),
Pyrexia (2),
Chest Pain (2),
Abdominal Pain (1),
Chills (1),
Tachycardia (1),
Viith Nerve Paralysis (1), more >>
|
